Free Trial

Bioventus (BVS) 10K Form and Latest SEC Filings 2026

Bioventus logo
$10.68 +0.51 (+5.01%)
Closing price 04:00 PM Eastern
Extended Trading
$11.03 +0.35 (+3.27%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Bioventus SEC Filings & Recent Activity

Bioventus (NASDAQ:BVS) has submitted 312+ documents to the U.S. Securities and Exchange Commission (SEC) since 2021. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Bioventus's financial statements. The most recent filing was a Form ARS submitted on April 22, 2026.

Form 4
Bioventus Inc. Reports Ownership Change on Apr. 14, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-K
Bioventus Files Annual Report on Mar. 5, 2026

The 10-K contains Bioventus's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Bioventus SEC Filing History

Browse Bioventus' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/22/2026 6:54 AM
Bioventus (1665988) Filer
Form DEFA14A
04/22/2026 7:04 AM
Bioventus (1665988) Filer
Form ARS
04/22/2026 6:51 AM
Bioventus (1665988) Filer
Form DEF 14A
04/14/2026 5:17 PM
Bioventus (1665988) Issuer
D'Adamio Anthony (1835184) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/14/2026 5:18 PM
Bioventus (1665988) Issuer
CHURCH KATRINA J (1204391) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/14/2026 5:18 PM
Bioventus (1665988) Issuer
Singleton Mark Leonard (1914936) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/14/2026 5:19 PM
Bioventus (1665988) Issuer
Cowdy Philip G. (1679773) Reporting
Form 4/A
04/14/2026 5:19 PM
Bioventus (1665988) Issuer
Cowdy Philip G. (1679773) Reporting
Form 4/A
03/24/2026 3:59 PM
Bioventus (1665988) Issuer
Singleton Mark Leonard (1914936) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 4:26 PM
Bioventus (1665988) Issuer
McMurry-Heath Michelle (1904156) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 9:47 AM
Bioventus (1665988) Subject
McMurry-Heath Michelle (1904156) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/05/2026 6:34 AM
Bioventus (1665988) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/05/2026 6:37 AM
Bioventus (1665988) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/05/2026 6:40 AM
Bioventus (1665988) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/18/2026 5:28 PM
Bioventus (1665988) Issuer
D'Adamio Anthony (1835184) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 5:29 PM
Bioventus (1665988) Issuer
CHURCH KATRINA J (1204391) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/18/2026 5:30 PM
Bioventus (1665988) Issuer
Singleton Mark Leonard (1914936) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 4:30 PM
Bioventus (1665988) Issuer
Claypoole Robert E (2005474) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/08/2025 4:02 PM
Bioventus (1665988) Issuer
NOHRA GUY P (1198330) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/04/2025 12:54 PM
Bioventus (1665988) Subject
NOHRA GUY P (1198330) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/25/2025 5:06 PM
Bioventus (1665988) Issuer
Dhankhar Ajay (2098243) Reporting
Form 3
Initial statement of beneficial ownership of securities  
11/17/2025 4:04 PM
Bioventus (1665988) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/10/2025 4:08 PM
Bioventus (1665988) Issuer
McMurry-Heath Michelle (1904156) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2025 6:37 AM
Bioventus (1665988) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/04/2025 6:39 AM
Bioventus (1665988) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/06/2025 6:42 AM
Bioventus (1665988) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/06/2025 6:45 AM
Bioventus (1665988) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/04/2025 7:15 AM
Bioventus (1665988) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/31/2025 7:12 AM
Bioventus (1665988) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/10/2025 4:49 PM
Bartholdson John A. (1382909) Reporting
Bioventus (1665988) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/05/2025 8:22 AM
Bartholdson John A. (1382909) Reporting
Bioventus (1665988) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 8:29 PM
Beyer Pat (1627985) Reporting
Bioventus (1665988) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 8:29 PM
Bioventus (1665988) Issuer
Cowdy Philip G. (1679773) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 8:29 PM
Bioventus (1665988) Issuer
HAWKINS WILLIAM A (1106508) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 8:30 PM
Bioventus (1665988) Issuer
Ladone Mary Kay (1760737) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 8:30 PM
Bioventus (1665988) Issuer
McMurry-Heath Michelle (1904156) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 8:30 PM
Bioventus (1665988) Issuer
NEELS GUIDO J (1222362) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 8:30 PM
Bioventus (1665988) Issuer
NOHRA GUY P (1198330) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 8:30 PM
Bioventus (1665988) Issuer
STALNECKER SUSAN M (1221375) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/04/2025 8:30 PM
Bioventus (1665988) Issuer
SUTTER MARTIN P (1017832) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
06/02/2025 4:10 PM
Bioventus (1665988) Filer
Form SD
Specialized Disclosure Report  
05/06/2025 6:36 AM
Bioventus (1665988) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/06/2025 6:38 AM
Bioventus (1665988) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Bioventus SEC Filings - Frequently Asked Questions

Bioventus (BVS) has submitted 312+ filings to the SEC since 2021. You can browse the complete history or filter by form type using the tools above.

Bioventus's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Bioventus's financial statements page.

The most recent filing was a Form ARS submitted on April 22, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:BVS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners